Galderma Group AG

Galderma Group AG is a global pure-play dermatology company headquartered in Zug, Switzerland. Established in 1981 as a joint venture between L'Oréal and Nestlé, the company's mission is to advance dermatology for every skin story by delivering innovative, science-based solutions to meet the dermatological needs of people worldwide. Galderma aims to enhance the quality of people's lives through its focus on skin health, offering products that protect, nourish, enhance, and treat skin conditions.

The company operates across three interconnected market segments: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Its portfolio includes well-known brands such as Restylane, Dysport (marketed as Azzalure in the EU), and Sculptra in Injectable Aesthetics; Cetaphil and ALASTIN in Dermatological Skincare; and prescription treatments like Differin, Benzac, Epiduo, Soolantra, Oracea, and the recently approved Nemluvio for Therapeutic Dermatology. Galderma's products are available in over 90 countries, serving both healthcare professionals and consumers.

Galderma became a publicly traded company in March 2024, listing on the SIX Swiss Exchange under the ticker GALD. This initial public offering (IPO) raised approximately CHF 2.3 billion, marking it as one of the largest IPOs in Europe and the biggest in Switzerland since 2017. Flemming Ørnskov has served as the Chief Executive Officer since October 2019, leading the company's strategy to outgrow the market through innovation and strong relationships with dermatologists and aesthetic practitioners.